Before a Diagnosis of Atezolizumab and Bevacizumab-associated Encephalitis Is Made, all other Possible Causes Should be Ruled Out.
作者信息
Finsterer Josef, Mehri Sounira
机构信息
Neurology Department, Neurology & Neurophysiology Center, Austria.
Biochemistry Laboratory, LR12ES05 "Nutrition-Functional Foods and Vascular Health", Faculty of Medicine, Tunisia.
出版信息
Intern Med. 2025 Jul 1;64(13):2088. doi: 10.2169/internalmedicine.4744-24. Epub 2024 Dec 5.
Abstract
摘要
相似文献
1
Before a Diagnosis of Atezolizumab and Bevacizumab-associated Encephalitis Is Made, all other Possible Causes Should be Ruled Out.在做出阿替利珠单抗和贝伐单抗相关脑炎的诊断之前，应排除所有其他可能的病因。
Intern Med. 2025 Jul 1;64(13):2088. doi: 10.2169/internalmedicine.4744-24. Epub 2024 Dec 5.
2
Patient with Atezolizumab-induced Encephalitis in Hepatocellular Carcinoma.肝细胞癌患者发生阿替利珠单抗诱导的脑炎。
Intern Med. 2025 Apr 15;64(8):1181-1187. doi: 10.2169/internalmedicine.4321-24. Epub 2024 Sep 11.
3
Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma-a multicentric study.阿替利珠单抗/贝伐珠单抗治疗不可切除肝细胞癌的安全性和有效性——一项多中心研究
BMC Cancer. 2025 Jul 1;25(1):1026. doi: 10.1186/s12885-025-14400-9.
4
Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma.免疫检查点抑制剂联合疗法在可切除和不可切除、适合栓塞治疗的肝细胞癌中的作用
Ther Adv Med Oncol. 2025 Jul 24;17:17588359251357719. doi: 10.1177/17588359251357719. eCollection 2025.
5
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.阿替利珠单抗联合贝伐珠单抗或仑伐替尼治疗肝细胞癌患者的临床结局：一项多中心真实世界研究。
J Cancer Res Clin Oncol. 2023 Aug;149(9):5591-5602. doi: 10.1007/s00432-022-04512-1. Epub 2022 Dec 13.
6
123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.用于诊断神经母细胞瘤的123I-间碘苄胍闪烁扫描术和18F-氟代脱氧葡萄糖正电子发射断层显像
Cochrane Database Syst Rev. 2015 Sep 29;2015(9):CD009263. doi: 10.1002/14651858.CD009263.pub2.
7
Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of chemotherapy in newly diagnosed WHO Grade II diffuse glioma in adults: update.神经外科医生大会关于化疗在成人新诊断的世界卫生组织二级弥漫性胶质瘤中作用的系统评价和循证指南：更新版
J Neurooncol. 2025 Jan;171(2):279-298. doi: 10.1007/s11060-024-04861-6. Epub 2024 Nov 20.
8
Classification and Regression Trees to Predict for Survival for Patients With Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab.基于阿替利珠单抗和贝伐珠单抗治疗的肝细胞癌患者的生存预测的分类和回归树。
JCO Clin Cancer Inform. 2024 Aug;8:e2300220. doi: 10.1200/CCI.23.00220.
9
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.单细胞RNA测序衍生的特征定义了晚期肝细胞癌对阿替利珠单抗+贝伐单抗的反应模式。
J Hepatol. 2025 Jun;82(6):1036-1049. doi: 10.1016/j.jhep.2024.12.016. Epub 2024 Dec 19.
10
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.大剂量化疗及自体造血干细胞救援用于高危神经母细胞瘤患儿
Cochrane Database Syst Rev. 2015 Oct 5;2015(10):CD006301. doi: 10.1002/14651858.CD006301.pub4.
引用本文的文献
1
A Case of a Patient with Atezolizumab-induced Encephalitis and Hepatocellular Carcinoma.一例阿替利珠单抗诱发脑炎合并肝细胞癌患者的病例
Intern Med. 2025 Jul 1;64(13):2089. doi: 10.2169/internalmedicine.4865-24. Epub 2024 Dec 5.
本文引用的文献
1
Patient with Atezolizumab-induced Encephalitis in Hepatocellular Carcinoma.肝细胞癌患者发生阿替利珠单抗诱导的脑炎。
Intern Med. 2025 Apr 15;64(8):1181-1187. doi: 10.2169/internalmedicine.4321-24. Epub 2024 Sep 11.
2
IgA Vasculitis during Atezolizumab Treatment.阿替利珠单抗治疗期间的IgA血管炎
Intern Med. 2024 Mar 15;63(6):881-882. doi: 10.2169/internalmedicine.2343-23. Epub 2023 Aug 2.
3
Bevacizumab-induced immunoglobulin A vasculitis with nephritis: A case report.贝伐单抗诱发的免疫球蛋白A血管炎伴肾炎：一例报告。
Medicine (Baltimore). 2019 Nov;98(45):e17870. doi: 10.1097/MD.0000000000017870.
Zotero 插件